Interleukins and cancer immunotherapy

Immunotherapy

Volumn 1, Issue 5, 2009, Pages 825-844

  Yoshimoto, Takayuki ^a   Morishima, Noriko ^a   Okumura, Masae ^a   Chiba, Yukino ^a   Mingli Xu, ^a   Mizuguchi, Junichiro ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Anticancer; Common chain family; IL 6 IL 12 heterodimeric cytokine family; Immunotherapy; Interleukin

Indexed keywords

CD123 ANTIGEN; CD131 ANTIGEN; CD4 ANTIGEN; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR2; CYTOKINE; GLYCOPROTEIN GP 130; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 10 RECEPTOR; INTERLEUKIN 11 RECEPTOR; INTERLEUKIN 12; INTERLEUKIN 12 RECEPTOR BETA1; INTERLEUKIN 12 RECEPTOR BETA2; INTERLEUKIN 13 RECEPTOR; INTERLEUKIN 15 RECEPTOR ALPHA; INTERLEUKIN 17 RECEPTOR; INTERLEUKIN 18 RECEPTOR; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 2 RECEPTOR BETA; INTERLEUKIN 21; INTERLEUKIN 24; INTERLEUKIN 4 RECEPTOR ALPHA; INTERLEUKIN 5 RECEPTOR ALPHA; INTERLEUKIN 6 RECEPTOR ALPHA; INTERLEUKIN 7 RECEPTOR ALPHA; INTERLEUKIN 9 RECEPTOR; UNINDEXED DRUG;

CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CELL PROLIFERATION; CLINICAL TRIAL; HOST RESISTANCE; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL COMMUNICATION; HUMANS; IMMUNOTHERAPY; INTERLEUKINS; NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 77953404476     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/IMT.09.46     Document Type: Review

References (159)

1. Dranoff G, Jaffee E, Lazenby A et al.: Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl Acad. Sci. USA 90, 3539-3543 (1993). (Pubitemid 23111402)
2. Eager R, Nemunaitis J: GM-CSF gene-transduced tumor vaccines. Mol. Ther. 12, 18-27 (2005).
3. Higano CS, Corman JM, Smith DC et al.: Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer 113, 975-984 (2008).
4. Leonard WJ: Cytokines and immunodeficiency diseases. Nat. Rev. Immunol. 1, 200-208 (2001).
5. Russell SM, Tayebi N, Nakajima H et al.: Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development. Science 270, 797-800 (1995).
6. Macchi P, Villa A, Giliani S et al.: Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature 377, 65-68 (1995).
7. Rosenberg SA, Lotze MT, Muul LM et al.: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl. J. Med. 316, 889-897 (1987).
8. Fisher RI, Coltman CA, Jr., Doroshow JH et al.: Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A Phase II clinical trial. Ann. Intern. Med. 108, 518-523 (1988).
9. Atkins MB, Sparano J, Fisher RI et al.: Randomized Phase II trial of high-dose interleukin-2 either alone or in combination with interferon α-2b in advanced renal cell carcinoma. J. Clin. Oncol. 11, 661-670 (1993). (Pubitemid 23105674)
10. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC: Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J. Clin. Oncol. 13, 688-696 (1995).
11. Yang JC, Topalian SL, Parkinson D et al.: Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report. J. Clin. Oncol. 12, 1572-1576 (1994). (Pubitemid 24244991)
12. Figlin RA, Belldegrun A, Moldawer N, Zeffren J, deKernion J: Concomitant administration of recombinant human interleukin-2 and recombinant interferon alpha;-2A: an active outpatient regimen in metastatic renal cell carcinoma. J. Clin. Oncol. 10, 414-421 (1992).
13. McDermott DF: Update on the application of interleukin-2 in the treatment of renal cell carcinoma. Clin. Cancer Res. 13, 716S-720S (2007).
14. Parton M, Gore M, Eisen T: Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer. J. Clin. Oncol. 24, 5584-5592 (2006).
15. Yang JC, Sherry RM, Steinberg SM et al.: Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J. Clin. Oncol. 21, 3127-3132 (2003).
16. McDermott DF, Regan MM, Clark JI et al.: Randomized Phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 23, 133-141 (2005).
17. Malek TR, Bayer AL: Tolerance, not immunity, crucially depends on IL-2. Nat. Rev. Immunol. 4, 665-674 (2004).
18. Sakaguchi S, Yamaguchi T, Nomura T, Ono M: Regulatory T cells and immune tolerance. Cell 133, 775-787 (2008).
19. + regulatory T cells by TGF-β induction of transcription factor Foxp3. J. Exp. Med. 198, 1875-1886 (2003).
20. - lymphocytes is thymus and proliferation independent. Cancer Res. 66, 4488-4495 (2006).
21. Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E: Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor a) monoclonal antibody. Cancer Res. 59, 3128-3133 (1999). (Pubitemid 29316012)
22. Schluns KS, Kieper WC, Jameson SC, Lefrancois L: Interleukin-7 mediates the homeostasis of naive and memory CD8 T cells in vivo. Nat. Immunol. 1, 426-432 (2000).
23. Fry TJ, Mackall CL: Interleukin-7: master regulator of peripheral T-cell homeostasis? Trends Immunol. 22, 564-571 (2001).
24. Fry TJ, Moniuszko M, Creekmore S et al.: IL-7 therapy dramatically alters peripheral T-cell homeostasis in normal and SIV-infected nonhuman primates. Blood 101, 2294-2299 (2003). (Pubitemid 36302072)
25. Storek J, Gillespy T, 3rd, Lu H et al.: Interleukin-7 improves CD4 T-cell reconstitution after autologous CD34 cell transplantation in monkeys. Blood 101, 4209-4218 (2003).
26. + T-regulatory cells. J. Immunother. 29, 313-319 (2006). (Pubitemid 44297299)
27. Sportes C, Hakim FT, Memon SA et al.: Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets. J. Exp. Med. 205, 1701-1714 (2008). (Pubitemid 351962032)
28. Andersson A, Yang SC, Huang M et al.: IL-7 promotes CXCR3 ligand-dependent T cell antitumor reactivity in lung cancer. J. Immunol. 182, 6951-6958 (2009).
29. Waldmann TA: The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat. Rev. Immunol. 6, 595-601 (2006).
30. Fehniger TA, Cooper MA, Caligiuri MA: Interleukin-2 and interleukin-15: immunotherapy for cancer. Cytokine Growth Factor Rev. 13, 169-183 (2002).
31. Lenardo MJ: Interleukin-2 programs mouse αβ T lymphocytes for apoptosis. Nature 353, 858-861 (1991).
32. Marks-Konczalik J, Dubois S, Losi JM et al.: IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice. Proc. Natl Acad. Sci. USA 97, 11445-11450 (2000). (Pubitemid 30780914)
33. + T cells for use in adoptive immunotherapy of established tumors. Nat. Med. 12, 335-341 (2006).
34. Mohamadzadeh M, Berard F, Essert G et al.: Interleukin 15 skews monocyte differentiation into dendritic cells with features of Langerhans cells. J. Exp. Med. 194, 1013-1020 (2001). (Pubitemid 32953269)
35. Ullrich E, Bonmort M, MIGnot G et al.: Trans-presentation of IL-15 dictates IFN-producing killer dendritic cells effector functions. J. Immunol. 180, 7887-7897 (2008).
36. Parrish-Novak J, Dillon SR, Nelson A et al.: Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 408, 57-63 (2000). (Pubitemid 30828256)
37. Ozaki K, Kikly K, Michalovich D, Young PR, Leonard WJ: Cloning of a type I cytokine receptor most related to the IL-2 receptor β chain. Proc. Natl Acad. Sci. USA 97, 11439-11444 (2000). • Along with [36], two papers that report clonings of IL-21 and IL-21R. (Pubitemid 30780913)
38. Leonard WJ, Spolski R: Interleukin-21: a modulator of lymphoid proliferation, apoptosis and differentiation. Nat. Rev. Immunol. 5, 688-698 (2005).
39. Skak K, Kragh M, Hausman D, Smyth MJ, Sivakumar PV: Interleukin 21: combination strategies for cancer therapy. Nat. Rev. Drug Discov. 7, 231-240 (2008).
40. Di Carlo E, Comes A, Orengo AM et al.: IL-21 induces tumor rejection by specific CTL and IFN-γ-dependent CXC chemokines in syngeneic mice. J. Immunol. 172, 1540-1547 (2004). (Pubitemid 38116798)
41. Furukawa J, Hara I, Nagai H, Yao A, Oniki S, Fujisawa M: Interleukin-21 gene transfection into mouse bladder cancer cells results in tumor rejection through the cytotoxic T lymphocyte response. J. Urol. 176, 1198-1203 (2006). (Pubitemid 44142565)
42. Ma HL, Whitters MJ, Konz RF et al.: IL-21 activates both innate and adaptive immunity to generate potent antitumor responses that require perforin but are independent of IFN-γ. J. Immunol. 171, 608-615 (2003).
43. Ugai S, Shimozato O, Kawamura K et al.: Expression of the interleukin-21 gene in murine colon carcinoma cells generates systemic immunity in the inoculated hosts. Cancer Gene Ther. 10, 187-192 (2003). (Pubitemid 36348679)
44. Shan B, Yu L, Shimozato O, Li Q, Tagawa M: Expression of interleukin-21 and -23 in human esophageal tumors produced antitumor effects in nude mice. Anticancer Res. 24, 79-82 (2004). (Pubitemid 38279691)
45. Ugai S, Shimozato O, Yu L et al.: Transduction of the IL-21 and IL-23 genes in human pancreatic carcinoma cells produces natural killer cell-dependent and -independent antitumor effects. Cancer Gene Ther. 10, 771-778 (2003). (Pubitemid 37243798)
46. + regulatory T cell depletion augments immunotherapy of micrometastases by an IL-21-secreting cellular vaccine. J. Immunol. 176, 1750-1758 (2006). (Pubitemid 43134320)
47. Zeng R, Spolski R, Finkelstein SE et al.: Synergy of IL-21 and IL-15 in regulating CD8' T cell expansion and function. J. Exp. Med. 201, 139-148 (2005). (Pubitemid 40130091)
48. Wang G, Tschoi M, Spolski R et al.: In vivo antitumor activity of interleukin 21 mediated by natural killer cells. Cancer Res. 63, 9016-9022 (2003). (Pubitemid 38064083)
49. Roda JM, Parihar R, Lehman A, Mani A, Tridandapani S, Carson WE, 3rd: Interleukin-21 enhances NK cell activation in response to antibody-coated targets. J. Immunol. 177, 120-129 (2006). (Pubitemid 43939123)
50. Smyth MJ, Hayakawa Y, Cretney E et al.: IL-21 enhances tumor-specific CTL induction by anti-DR5 antibody therapy. J. Immunol. 176, 6347-6355 (2006).
51. Smyth MJ, Teng MW, Sharkey J et al.: Interleukin-21 enhances antibody-mediated tumor rejection. Cancer Res. 68, 3019-3025 (2008). (Pubitemid 351556303)
52. Smyth MJ, Wallace ME, Nutt SL, Yagita H, Godfrey DI, Hayakawa Y: Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of Cancer J. Exp. Med. 201, 1973-1985 (2005).
53. Davis ID, Skrumsager BK, Cebon J et al.: An open-label, two-arm, Phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma. Clin. Cancer Res. 13, 3630-3636 (2007). (Pubitemid 46955126)
54. Thompson JA, Curti BD, Redman BG et al.: Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma. J. Clin. Oncol. 26, 2034-2039 (2008).
55. Davis ID, Brady B, Kefford RF et al. Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a Phase IIa trial. Clin. Cancer Res. 15, 2123-2129 (2009).
56. Rose-John S, Heinrich PC: Soluble receptors for cytokines and growth factors: generation and biological function. Biochem. J. 300 (Pt 2), 281-290 (1994). (Pubitemid 24167878)
57. Peters M, Schirmacher P, Goldschmitt J et al.: Extramedullary expansion of hematopoietic progenitor cells in interleukin (IL)-6-sIL-6R double transgenic mice. J. Exp. Med. 185, 755-766 (1997). (Pubitemid 27098159)
58. Sui X, Tsuji K, Tanaka R et al.: gp130 and c-Kit signalings synergize for ex vivo expansion of human primitive hemopoietic progenitor cells. Proc. Natl Acad. Sci. USA 92, 2859-2863 (1995).
59. Hirota H, Kiyama H, Kishimoto T, Taga T: Accelerated nerve regeneration in mice by upregulated expression of interleukin (IL) 6 and IL-6 receptor after trauma. J. Exp. Med. 183, 2627-2634 (1996). (Pubitemid 26192371)
60. Fischer M, Goldschmitt J, Peschel C et al.: I. A bioactive designer cytokine for human hematopoietic progenitor cell expansion. Nat. Biotechnol. 15, 142-145 (1997).
61. Cressman DE, Greenbaum LE, DeAngelis RA et al.: Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science 274, 1379-1383 (1996).
62. Kobayashi M, Fitz L, Ryan M et al.: Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J. Exp. Med. 170, 827-845 (1989). (Pubitemid 19226667)
63. Stern AS, Podlaski FJ, Hulmes JD et al.: Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells. Proc. Natl Acad. Sci. USA 87, 6808-6812 (1990). • Along with [62], two papers that report a cloning of IL-12.
64. Trinchieri G: Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu. Rev. Immunol. 13, 251-276 (1995).
65. Gately MK, Renzetti LM, Magram J et al.: The interleukin-12/interleukin- 12-receptor system: role in normal and pathologic immune responses. Annu. Rev. Immunol. 16, 495-521 (1998). (Pubitemid 28183374)
66. Trinchieri G: Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 3, 133-146 (2003).
67. Oppmann B, Lesley R, Blom B et al.: Novel pl9 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 13, 715-725 (2000). • Reports a cloning of IL-23.
68. + T cells. Immunity 16, 779-790 (2002). • Reports a cloning of IL-27. (Pubitemid 34786477)
69. Kastelein RA, Hunter CA, Cua DJ: Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation. Annu. Rev. Immunol. 25, 221-242 (2007).
70. Parham C, Chirica M, Timans J et al.: A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rβ1 and a novel cytokine receptor subunit, IL-23R. J. Immunol. 168, 5699-5708 (2002).
71. Yang XO, Panopoulos AD, Nurieva R et al.: STAT3 regulates cytokine-mediated generation of inflammatory helper T cells. J. Biol. Chem. 282(13), 9358-9363 (2007).
72. Aggarwal S, Ghilardi N, Xie MH, de Sauvage FJ, Gurney AL: Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J. Biol. Chem. 278, 1910-1914 (2003).
73. Murphy CA, Langrish CL, Chen Y et al.: Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J. Exp. Med. 198, 1951-1957 (2003).
74. Langrish CL, Chen Y, Blumenschein WM et al.: IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 201, 233-240 (2005). (Pubitemid 40189432)
75. Cua DJ, Sherlock J, Chen Y et al.: Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421, 744-748 (2003). (Pubitemid 36227625)
76. Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B: TGFβ in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 24, 179-189 (2006). (Pubitemid 43214587)
77. Pflanz S, Hibbert L, Mattson J et al.: WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27. J. Immunol. 172, 2225-2231 (2004). (Pubitemid 38182370)
78. Villarino AV, Huang E, Hunter CA: Understanding the pro- and anti-inflammatory properties of IL-27. J. Immunol. 173, 715-720 (2004). (Pubitemid 38924243)
79. Hunter CA: New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. Nat. Rev. Immunol. 5, 521-531 (2005).
80. Collison LW, Workman CJ, Kuo TT et al.: The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 450, 566-569 (2007).
81. Niedbala W, Wei XQ, Cai B et al.: IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. Eur. J. Immunol. 37, 3021-3029 (2007). (Pubitemid 350131282)
82. Brunda MJ, Luistro L, Warrier RR et al.: Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J. Exp. Med. 178, 1223-1230 (1993). ■■ First paper that reports antitumor activity of IL-12.
83. Colombo MP, Trinchieri G: Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev. 13, 155-168 (2002).
84. Wigginton JM, Gruys E, Geiselhart L et al.: IFN-γ and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy. J. Clin. Invest. 108, 51-62 (2001). (Pubitemid 32634922)
85. Coughlin CM, Salhany KE, Wysocka M et al.: Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. J. Clin. Invest. 101, 1441-1452 (1998). (Pubitemid 28145262)
86. Zitvogel L, Robbins PD, Storkus WJ et al.: Interleukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors. Eur. J. Immunol. 26, 1335-1341 (1996). (Pubitemid 26001070)
87. Cui J, Shin T, Kawano T et a.l: Requirement for Vα14 NKT cells in IL-12-mediated rejection of tumors. Science 278, 1623-1626 (1997). (Pubitemid 27516281)
88. Atkins MB, Robertson MJ, Gordon M et al.: Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin. Cancer Res. 3, 409-417 (1997). (Pubitemid 27158065)
89. Motzer RJ, Rakhit A, Thompson JA et al.: Randomized multicenter Phase II trial of subcutaneous recombinant human interleukin-12 versus interferon-α 2a for patients with advanced renal cell carcinoma. J. Interferon Cytokine Res. 21, 257-263 (2001). (Pubitemid 32680910)
90. Del Vecchio M, Bajetta E, Canova S et al.: Interleukin-12: biological properties and clinical application. Clin. Cancer Res. 13, 4677-4685 (2007). (Pubitemid 47294773)
91. Golab J, Zagozdzon R: Antitumor effects of interleukin-12 in pre-clinical and early clinical studies (review). Int. J. Mol. Med. 3, 537-544 (1999).
92. Rook AH, Wood GS, Yoo EK et al.: Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses. Blood 94, 902-908 (1999).
93. Car BD, Eng VM, Lipman JM, Anderson TD: The toxicology of interleukin-12: a review. Toxicol. Pathol. 27, 58-63 (1999).
94. Marshall E: Cancer trial of interleukin-12 halted. Science (Wash. DC). 268, 1555 (1995).
95. Car BD, Eng VM, Schnyder B et al.: Role of interferon-γ in interleukin 12-induced pathology in mice. Am. J. Pathol. 147, 1693-1707 (1995).
96. Ryffel B: Interleukin-12: role of interferon-γ in IL-12 adverse effects. Clin. Immunol. Immunopathol. 83, 18-20 (1997).
97. Haicheur N, Escudier B, Dorval T et al.: Cytokines and soluble cytokine receptor induction after IL-12 administration in cancer patients. Clin. Exp. Immunol. 119, 28-37 (2000). (Pubitemid 30064588)
98. Portielje JE, Lamers CH, Kruit WH et al.: Repeated administrations of interleukin (IL)-12 are associated with persistently elevated plasma levels of IL-10 and declining IFN-γ, tumor necrosis factor-α, IL-6, and IL-8 responses. Clin. Cancer Res. 9, 76-83 (2003).
99. Bajetta E, Del Vecchio M, Mortarini R et al.: Pilot study of subcutaneous recombinant human interleukin 12 in metastatic melanoma. Clin. Cancer Res. 4, 75-85 (1998). (Pubitemid 28062880)
100. + T cells in melanoma patients receiving interleukin 12. Cancer Res. 60, 3559-3568 (2000).
101. Beyer M, Schultze JL: Regulatory T cells in cancer. Blood 108, 804-811 (2006).
102. Lo CH, Lee SC, Wu PY et al.: Antitumor and antimetastatic activity of IL-23. J. Immunol. 171, 600-607 (2003).
103. Wang YQ, Ugai S, Shimozato O et al.: Induction of systemic immunity by expression of interleukin-23 in murine colon carcinoma cells. Int. J. Cancer 105, 820-824 (2003). (Pubitemid 36706106)
104. Kaiga T, Sato M, Kaneda H, Iwakura Y, Takayama T, Tahara H: Systemic administration of IL-23 induces potent antitumor immunity primarily mediated through Th1-type response in association with the endogenously expressed IL-12. J. Immunol. 178, 7571-7580 (2007). (Pubitemid 46898026)
105. Hu J, Yuan X, Belladonna ML et al.: Induction of potent antitumor immunity by intratumoral injection of interleukin 23-transduced dendritic cells. Cancer Res. 66, 8887-8896 (2006). (Pubitemid 44449207)
106. Langowski JL, Zhang X, Wu L et al.: IL-23 promotes tumour incidence and growth. Nature 442, 461-465 (2006). ■■ Demonstrates that inflammation induced by IL-23 promotes tumor incidence and growth. (Pubitemid 44264796)
107. Kortylewski M, Xin H, Kujawski M et al.: Regulation of the IL-23 and IL-12 balance by STAT3 signaling in the tumor microenvironment. Cancer Cell. 15, 114-123 (2009).
108. Szabo SJ, Kim ST, Costa GL, Zhang X, Fathman CG, Glimcher LH: A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 100, 655-669 (2000).
109. Takeda A, Hamano S, Yamanaka A et al.: Cutting edge: role of IL-27/WSX-1 signaling for induction of T-bet through activation of STAT1 during initial Th1 commitment. J. Immunol. 170, 4886-4890 (2003). (Pubitemid 36554716)
110. Hibbert L, Pflanz S, De Waal Malefyt R, Kastelein RA: IL-27 and IFN-α signal via STAT1 and STAT3 and induce T-bet and IL-12Rβ2 in naive T cells. J Interferon Cytokine Res. 23, 513-522 (2003). (Pubitemid 37130074)
111. + T cells. J. Immunol. 173, 3871-3877 (2004).
112. Villarino A, Hibbert L, Lieberman L et al.: The IL-27R (WSX-1) is required to suppress T cell hyperactivity during infection. Immunity 19, 645-655 (2003). (Pubitemid 37490790)
113. Stumhofer JS, Laurence A, Wilson EH et al.: Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system. Nat. Immunol. 7, 937-945 (2006). (Pubitemid 44263907)
114. Hamano S, Himeno K, Miyazaki Y et al.: WSX-1 is required for resistance to Trypanosoma cruzi infection by regulation of proinflammatory cytokine production. Immunity 19, 657-667 (2003). (Pubitemid 37490791)
115. Artis D, Villarino A, Silverman M et al.: The IL-27 receptor (WSX-1) is an inhibitor of innate and adaptive elements of type 2 immunity. J. Immunol. 173, 5626-5634 (2004). (Pubitemid 39392150)
116. Yamanaka A, Hamano S, Miyazaki Y et al.: Hyperproduction of proinflammatory cytokines by WSX-1-deficient NKT cells in concanavalin A-induced hepatitis. J. Immunol. 172, 3590-3596 (2004). (Pubitemid 38337940)
117. Batten M, Li J, Yi S et al.: Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells. Nat. Immunol. 7, 929-936 (2006). (Pubitemid 44263906)
118. Stumhofer JS, Silver JS, Laurence A et al.: Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10. Nat. Immunol. 8, 1363-1371 (2007). (Pubitemid 350131173)
119. Fitzgerald DC, Zhang GX, El-Behi M et al.: Suppression of autoimmune inflammation of the central nervous system by interleukin 10 secreted by interleukin 27-stimulated T cells. Nat. Immunol. 8, 1372-1379 (2007). (Pubitemid 350131174)
120. Batten M, Kljavin NM, Li J, Walter MJ, de Sauvage FJ, Ghilardi N: Cutting edge: IL-27 is a potent inducer of IL-10 but not FoxP3 in murine T cells. J. Immunol. 180, 2752-2756 (2008).
121. Awasthi A, Carrier Y, Peron JP et al.: A dominant function for interleukin 27 in generating interleukin 10-producing anti-inflammatory T cells. Nat. Immunol. 8, 1380-1389 (2007). (Pubitemid 350131175)
122. Hisada M, Kamiya S, Fujita K et al.: Potent antitumor activity of interleukin-27. Cancer Res. 64, 1152-1156 (2004). ■■ First paper that reports antitumor activity of IL-27.
123. + T cells. J. Immunol. 173, 7170-7182 (2004).
124. Salcedo R, Hixon JA, Stauffer JK et al.: Immunologic and therapeutic synergy of IL-27 and IL-2: enhancement of T cell sensitization, tumor-specific CTL reactivity and complete regression of disseminated neuroblastoma metastases in the liver and bone marrow. J. Immunol. 182, 4328-4338 (2009).
125. Chiyo M, Shimozato O, Iizasa T, Fujisawa T, Tagawa M: Antitumor effects produced by transduction of dendritic cells-derived heterodimeric cytokine genes in murine colon carcinoma cells. Anticancer Res. 24, 3763-3767 (2004). (Pubitemid 40468663)
126. Chiyo M, Shimozato O, Yu L et al.: Expression of IL-27 in murine carcinoma cells produces antitumor effects and induces protective immunity in inoculated host animals. Int. J. Cancer 115, 437-442 (2005). (Pubitemid 40663748)
127. Oniki S, Nagai H, Horikawa T et al.: Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma. Cancer Res. 66, 6395-6404 (2006).
128. Liu L, Wang S, Shan B et al.: IL-27-mediated activation of natural killer cells and inflammation produced antitumour effects for human oesophageal carcinoma cells. Scand J. Immunol. 68, 22-29 (2008). (Pubitemid 351798398)
129. Hu P, Hu HD, Chen M et al.: Expression of interleukins-23 and 27 leads to successful gene therapy of hepatocellular carcinoma. Mol. Immunol. 46, 1654-1662 (2009).
130. Matsui M, Kishida T, Nakano H et al.: Interleukin-27 activates natural killer cells and suppresses NK-resistant head and neck squamous cell carcinoma through inducing antibody-dependent cellular cytotoxicity. Cancer Res. 69, 2523-2530 (2009).
131. Shimizu M, Shimamura M, Owaki T et al.: Antiangiogenic and antitumor activities of IL-27. J. Immunol. 176, 7317-7324 (2006).
132. Yoshimoto T, Morishima N, Mizoguchi I et al.: Antiproliferative activity of IL-27 on melanoma. J. Immunol. 180, 6527-6535 (2008).
133. Okamura H, Tsutsi H, Komatsu T et al.: Cloning of a new cytokine that induces IFN-γ production by T cells. Nature 378, 88-91 (1995). ■ Reports a cloning of IL-18.
134. Micallef MJ, Yoshida K, Kawai S et al.: In vivo antitumor effects of murine interferon-γ-inducing factor/interleukin-18 in mice bearing syngeneic Meth A sarcoma malignant ascites. Cancer Immunol. Immunother. 43, 361-367 (1997). (Pubitemid 27102222)
135. Jonak ZL, Trulli S, Maier C et al.: High-dose recombinant interleukin-18 induces an effective Th1 immune response to murine MOPC-315 plasmacytoma. J. Immunother. 25(Suppl. 1), S20-S27 (2002). (Pubitemid 34260754)
136. Osaki T, Peron JM, Cai Q et al.: IFN-γ-inducing factor/IL-18 administration mediates IFN-γ- and IL-12-independent antitumor effects. J. Immunol. 160, 1742-1749 (1998). (Pubitemid 28106460)
137. Ju DW, Tao Q Lou G et al.: Interleukin 18 transfection enhances antitumor immunity induced by dendritic cell-tumor cell conjugates. Cancer Res. 61, 3735-3740 (2001).
138. Nakata A, Tsujimura T, Sugihara A et al.: Inhibition by interleukin 18 of osteolytic bone metastasis by human breast cancer cells. Anticancer Res. 19, 4131-4138 (1999).
139. Jiang H, Lin JJ, Su ZZ, Goldstein NI, Fisher PB: Subtraction hybridization identifies a novel melanoma differentiation associated gene, MDA-7, modulated during human melanoma differentiation, growth and progression. Oncogene 11, 2477-2486 (1995). (Pubitemid 26023815)
140. Sauane M, Gopalkrishnan RV, Sarkar D et al.: MDA-7/IL-24: novel cancer growth suppressing and apoptosis inducing cytokine. Cytokine Growth Factor Rev. 14, 35-51 (2003). (Pubitemid 36098430)
141. Ekmekcioglu S, Ellerhorst J, Mhashilkar AM et al.: Down-regulated melanoma differentiation associated gene (MDA-7) expression in human melanomas. Int. J. Cancer 94, 54-59 (2001). (Pubitemid 32801752)
142. Lebedeva IV, Su ZZ, Chang Y, Kitada S, Reed JC, Fisher PB: The cancer growth suppressing gene MDA-7 induces apoptosis selectively in human melanoma cells. Oncogene 21, 708-718 (2002). (Pubitemid 34146283)
143. Jiang H, Su ZZ, Lin JJ, Goldstein NI, Young CS, Fisher PB: The melanoma differentiation associated gene MDA-7 suppresses cancer cell growth. Proc. Natl Acad. Sci. USA 93, 9160-9165 (1996). ■ Reports a cloning of MDA-7/IL-24. (Pubitemid 26282035)
144. Lebedeva IV, Sarkar D, Su ZZ et al.: Bcl-2 and Bcl-x(L) differentially protect human prostate cancer cells from induction of apoptosis by melanoma differentiation associated gene-7, MDA-7/IL-24. Oncogene 22, 8758-8773 (2003).
145. Saeki T, Mhashilkar A, Swanson X et al.: Inhibition of human lung cancer growth following adenovirus-mediated MDA-7 gene expression in vivo. Oncogene 21, 4558-4566 (2002). (Pubitemid 34785732)
146. Su ZZ, Madireddi MT, Lin JJ et al.: The cancer growth suppressor gene MA4-7 selectively induces apoptosis in human breast cancer cells and inhibits tumor growth in nude mice. Proc. Natl Acad. Sci. USA 95, 14400-14405 (1998).
147. Lebedeva IV, Emdad L, Su ZZ et al.: MDA-7/IL-24, novel anticancer cytokine: focus on bystander antitumor, radiosensitization and antiangiogenic properties and overview of the Phase I clinical experience (Review). Int. J. Oncol. 31, 985-1007 (2007).
148. Cunningham CC, Chada S, Merritt JA et al.: Clinical and local biological effects of an intratumoral injection of MDA-7 (IL24; INGN 241) in patients with advanced carcinoma: a Phase I study. Mol. Ther. 11, 149-159 (2005). (Pubitemid 40012009)
149. Kotenko SV, Gallagher G, Baurin VV et al.: IFN-λs mediate
150. Sheppard P, Kindsvogel W, Xu W et al.: IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat. Immunol. 4, 63-68 (2003). ■ Along with [149], two papers that report clonings of IL-28/IL-29.
151. Lasfar A, Lewis-Antes A, Smirnov SV et al.: Characterization of the mouse IFN-λ ligand-receptor system: IFN-λs exhibit antitumor activity against B16 melanoma. Cancer Res. 66, 4468-4477 (2006).
152. Numasaki M, Tagawa M, Iwata F et al.: IL-28 elicits antitumor responses against murine fibrosarcoma. J. Immunol. 178, 5086-5098 (2007). (Pubitemid 46595292)
153. Sato A, Ohtsuki M, Hata M, Kobayashi E, Murakami T: Antitumor activity of IFN-λ in murine tumor models. J. Immunol. 176, 7686-7694 (2006). (Pubitemid 43849069)
154. Ferrari M: Cancer nanotechnology: opportunities and challenges. Nat. Rev. Cancer 5, 161-171 (2005).
155. Aste-Amezaga M, D'Andrea A, Kubin M, Trinchieri G: Cooperation of natural killer cell stimulatory factor/interleukin-12 with other stimuli in the induction of cytokines and cytotoxic cell-associated molecules in human T and NK cells. Cell Immunol. 156, 480-492 (1994). (Pubitemid 24252901)
156. Kubin M, Kamoun M, Trinchieri G: Interleukin 12 synergizes with B7/CD28 interaction in inducing efficient proliferation and cytokine production of human T cells. J. Exp. Med. 180, 211-222 (1994). (Pubitemid 24181070)
157. Dannull J, Su Z, Rizzieri O et al.: Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J. Clin. Invest. 115, 3623-3633 (2005). (Pubitemid 43121851)
158. Tato CM, Cua DJ: SnapShot: cytokines II. Cell 132, 500 (2008).
159. Tato CM, Cua DJ: SnapShot: cytokines I. Cell 132, 324 e321 (2008).